RxDoctor Payments Data

Malvin Keller, MD

Cardiovascular Disease · Edison, NJNPI 1013967520

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 89 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$395
  • Medtronic$348
  • Boston Scientific$232
  • Heartflow, Inc.$224
  • Pfizer$168
  • Atricure, Inc.$131
  • plus $523 from 15 others

What the payments were for

  • Travel & lodging$23312%
  • Food & beverage$1,78788%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$367,468
Medicare patients
1,126
Services billed
4,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban482$540,608
VyndamaxTafamidis16$350,717
Repatha SureclickEvolocumab159$157,360
XareltoRivaroxaban102$125,598
JardianceEmpagliflozin75$89,919
EntrestoSacubitril/Valsartan59$79,770
OzempicSemaglutide68$77,994
MultaqDronedarone Hcl33$64,934
BrilintaTicagrelor59$52,057
JanuviaSitagliptin Phosphate21$27,940
FarxigaDapagliflozin Propanediol19$27,735
EdarbiAzilsartan Medoxomil50$27,244
JanumetSitagliptin Phos/Metformin Hcl13$21,609
Breo ElliptaFluticasone/Vilanterol38$19,601
EdarbyclorAzilsartan Med/Chlorthalidone23$14,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$168$891,325498 claims
Johnson & JohnsonXarelto$57$125,598102 claims
NovartisEntresto$54$79,77059 claims
Novo NordiskOzempic$395$77,99468 claims
Sanofi-aventis U.S. LLCMultaq$17$64,93433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →